In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Archie Lovatt Life Sciences Biosafety Scientific Director at SGS.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Archie, covering:
Being motivated by saving lives and seeing your contribution make a real impact on the world. Following your heart and not chasing the money.
Seeing Covid-19 drugs developed in a parallel rather than sequential way, helping accelerate the process while not compromising on safety.
Being acquired by SGS yet maintaining the entrepreneurial spirit to explore and innovate.
The long term value to patients of now having more platform technologies and a greater operational infrastructure to deal with disease areas.
Archie is a vaccine, gene and cell therapy biosafety testing expert. He graduated with a PhD in molecular microbiology and has been in the industry for the best part of 30 years. During this time, he founded a CRO called Vitrology, which was then acquired by SGS in 2012 and has since served on the board as Scientific Operations Director. He was also voted into the top 100 most influential people in human medicine development and manufacture.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.